- Home
- SFWL vs WHWK Comparison
SFWL vs WHWK Comparison
Compare SFWL & WHWK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SFWL
- WHWK
- Stock Information
- Founded
- SFWL 2001
- WHWK 2007
- Country
- SFWL China
- WHWK United States
- Employees
- SFWL N/A
- WHWK N/A
- Industry
- SFWL Trucking Freight/Courier Services
- WHWK Biotechnology: Pharmaceutical Preparations
- Sector
- SFWL Industrials
- WHWK Health Care
- Exchange
- SFWL Nasdaq
- WHWK Nasdaq
- Market Cap
- SFWL 82.5M
- WHWK 95.2M
- IPO Year
- SFWL 2023
- WHWK N/A
- Fundamental
- Price
- SFWL $0.91
- WHWK $2.14
- Analyst Decision
- SFWL
- WHWK
- Analyst Count
- SFWL 0
- WHWK 0
- Target Price
- SFWL N/A
- WHWK N/A
- AVG Volume (30 Days)
- SFWL 6.9K
- WHWK 5.2M
- Earning Date
- SFWL 08-27-2025
- WHWK 11-05-2025
- Dividend Yield
- SFWL N/A
- WHWK N/A
- EPS Growth
- SFWL 31.68
- WHWK N/A
- EPS
- SFWL 0.14
- WHWK N/A
- Revenue
- SFWL $540,461,000.00
- WHWK $21,596,000.00
- Revenue This Year
- SFWL N/A
- WHWK N/A
- Revenue Next Year
- SFWL N/A
- WHWK N/A
- P/E Ratio
- SFWL $6.48
- WHWK N/A
- Revenue Growth
- SFWL 21.10
- WHWK N/A
- 52 Week Low
- SFWL $0.84
- WHWK $1.39
- 52 Week High
- SFWL $1.38
- WHWK $3.81
- Technical
- Relative Strength Index (RSI)
- SFWL 39.61
- WHWK 46.90
- Support Level
- SFWL $0.91
- WHWK $2.12
- Resistance Level
- SFWL $1.00
- WHWK $2.30
- Average True Range (ATR)
- SFWL 0.04
- WHWK 0.23
- MACD
- SFWL 0.00
- WHWK -0.04
- Stochastic Oscillator
- SFWL 43.09
- WHWK 11.41
About SFWL Shengfeng Development Limited
Shengfeng Development Ltd is a holding company. Through its subsidiaries, it offers contract logistics services in China. The contract logistics services offered by the company include planning and designing supply chains, designing facilities, processing orders, collecting payments, managing inventories, and providing client services.
About WHWK Whitehawk Therapeutics Inc. Common Stock
Whitehawk Therapeutics Inc is a preclinical stage oncology therapeutics. The company is engaged in applying technologies to established tumor biology to efficiently deliver improved cancer treatments. The company's three-asset ADC portfolio is engineered to overcome the limitations of first-generation predecessors to deliver a meaningful impact for patients with difficult-to-treat cancers.